Changmao Bio (00954.HK) announced that for the six months ended June 30, 2024, the group's sales revenue was RMB 313,802,000, an increase of about 5.8% from RMB 296,608,000 in the same period last year; the net loss attributable to shareholders of the company was approximately RMB 18,786,000. The net income attributable to shareholders of the company in the same period last year was approximately RMB 4,157,000.
常茂生物(00954.HK)中期销售收入3.14亿元 同比提高约5.8%
Changmao Bio (00954.HK) had a mid-year sales revenue of approximately 0.314 billion yuan, a year-on-year increase of about 5.8%.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.